USP Class VI has occupied a central place in pharmaceutical packaging specifications for decades. For many organizations, “Class VI compliant” became a convenient shorthand for biocompatibility; an easy way to demonstrate that a material had passed a recognized biological benchmark.

However, as regulatory expectations and scientific understanding have evolved, it has become increasingly clear that USP Class VI alone is no longer sufficient to demonstrate the safety of pharmaceutical packaging systems. In some cases, continued reliance on Class VI can actually obscure risk rather than clarify it.

What USP Class VI Was Designed to Do

USP Class VI testing was developed to evaluate the biological reactivity of materials that may come into **direct contact with tissue**. The test battery focuses on systemic toxicity, intracutaneous reactivity, and implantation effects following exposure to material extracts.

This framework made sense for its original purpose. When materials are intended to contact tissue directly, broad in vivo testing can provide a conservative safety signal. Class VI testing reflects that device-oriented mindset.

The problem is not that Class VI testing is flawed, it is that its underlying assumptions do not align well with how pharmaceutical packaging materials are actually used.

Why Class VI Falls Short for Packaging Applications

Pharmaceutical packaging materials rarely contact patient tissue directly. Instead, any potential patient exposure occurs through **chemical migration** into the drug product, followed by administration via the intended route.

Class VI testing does not evaluate this pathway. It assesses bulk material extracts under exaggerated conditions without linking results to realistic exposure, dose, or duration. As a result, Class VI outcomes can be difficult (or impossible) to interpret in a patient-centric context.

A material may pass Class VI testing yet still release trace-level compounds that are clinically relevant. Conversely, a Class VI result may trigger concern even when actual patient exposure is negligible. In both cases, the test result fails to answer the most important question: *Is the patient at risk under intended use conditions?*

How Regulatory Expectations Have Changed

Regulatory agencies have gradually moved away from accepting Class VI as a standalone demonstration of safety for packaging systems. Instead, they increasingly expect a **risk-based evaluation** grounded in material characterization, exposure assessment, and scientific rationale.

This evolution is reflected directly in modern USP chapters. USP <381>, USP <661.1>, and USP <661.2> emphasize material composition, physicochemical properties, and extractables and leachables considerations. Revised USP <87> expands in vitro biological screening options. USP <1031> provides the framework for integrating these elements into a cohesive assessment.

Notably, USP <1031> does not position Class VI as a decision endpoint. Instead, it treats historical biological data as contextual information that must be interpreted alongside chemistry and toxicology.

The Risks of Over-Reliance on Class VI

Continued reliance on Class VI as a primary acceptance criterion introduces several risks:

– **False confidence**, when a passing result masks relevant chemical migration risk
– **Unnecessary testing**, when Class VI is applied reflexively without exposure justification
– **Audit vulnerability**, when inspectors question the relevance of legacy testing
– **Change-control friction**, when outdated specifications force repeated animal testing

These risks become more pronounced as organizations approach the 2026 implementation of revised USP chapters.

What Replaces Class VI in a Modern Strategy

Retiring Class VI does not mean eliminating biological evaluation. It means replacing a blunt instrument with a more precise toolkit.

A modern packaging biocompatibility strategy typically includes:
– Material composition review and supplier transparency
– Chemical characterization focused on realistic extraction conditions
– In vitro biological screening under USP <87> to identify overt reactivity
– Toxicological risk assessment to translate chemistry into patient risk
– Conditional use of USP <88> only when uncertainty remains

Within this framework, Class VI data (if available) may still provide historical context. However, it should not serve as the primary basis for safety decisions.

Addressing Legacy Specifications and Expectations

One of the most practical challenges faced by packaging teams is how to manage existing specifications that explicitly reference USP Class VI. Eliminating these references overnight is rarely feasible.

Instead, many organizations are adopting a phased approach. Class VI language may be retained temporarily while new risk-based criteria are introduced alongside it. Over time, specifications can be updated to reference USP <87>, USP <1031>, and exposure-based justification rather than legacy classifications.

This approach maintains continuity while aligning programs with modern expectations.

Why This Matters Now

As revised USP chapters approach their effective date in December 2026, reliance on Class VI will become increasingly difficult to defend. Inspectors are likely to expect evidence that organizations understand and are applying the updated framework.

Packaging teams that proactively transition away from Class VI-centric thinking will be better positioned to:
– Reduce unnecessary animal testing
– Streamline change control
– Improve audit defensibility
– Support innovation and material changes

The Bottom Line

USP Class VI played an important role in the historical development of material safety testing. But for pharmaceutical packaging, it is no longer enough.

Modern biocompatibility expectations demand an exposure-driven, risk-based approach that integrates chemistry, biology, and toxicology. Retiring Class VI as a primary acceptance criterion is not about lowering standards, it is about applying the right science to protect patients more effectively.